OBJECTIVE: To determine if differences in outcome exist between diabetic and non-diabetic patients who present to the Emergency Department (ED) with acute ischemic stoke (AIS) and elevated blood glucose. METHODS: The study population consisted of 447 consecutive patients who presented to the ED with AIS within 24 h of symptom onset and had blood glucose measured on presentation. Hyperglycemia was defined as >130 mg/dl. Outcomes studied included infarct volume, stroke severity (NIH Stroke Scale), functional impairment (modified Rankin Score), and 90-day mortality. Patients with hyperglycemia were then stratified into those with and without a prior history of diabetes mellitus (DM) for the purposes of analysis. RESULTS: Patients with hyperglycemia exhibited significantly greater stroke severity (P = 0.002) and greater functional impairment (P = 0.004) than those with normoglycemia. Patients with hyperglycemia were 2.3 times more likely to be dead at 90 days compared to those with normal glucose (P < 0.001). Stroke severity (P < 0.001) and functional impairment (P < 0.001) were both significantly worse in patients with hyperglycemia and no prior history of DM, when compared to patients with hyperglycemia and previously diagnosed DM. Among the patients without a prior history of DM, patients with hyperglycemia were 3.4 times more likely to die within 90 days (P < 0.001) when compared with patients with normoglycemia. In contrast, the hazard ratio was 1.6 among the patients with DM (P = 0.66). CONCLUSION: Hyperglycemia on presentation is associated with significantly poorer outcomes following AIS. Patients with hyperglycemia and no prior history of DM have a particularly poor prognosis, worse than that for patients with known diabetes and hyperglycemia.
OBJECTIVE: To determine if differences in outcome exist between diabetic and non-diabeticpatients who present to the Emergency Department (ED) with acute ischemic stoke (AIS) and elevated blood glucose. METHODS: The study population consisted of 447 consecutive patients who presented to the ED with AIS within 24 h of symptom onset and had blood glucose measured on presentation. Hyperglycemia was defined as >130 mg/dl. Outcomes studied included infarct volume, stroke severity (NIH Stroke Scale), functional impairment (modified Rankin Score), and 90-day mortality. Patients with hyperglycemia were then stratified into those with and without a prior history of diabetes mellitus (DM) for the purposes of analysis. RESULTS:Patients with hyperglycemia exhibited significantly greater stroke severity (P = 0.002) and greater functional impairment (P = 0.004) than those with normoglycemia. Patients with hyperglycemia were 2.3 times more likely to be dead at 90 days compared to those with normal glucose (P < 0.001). Stroke severity (P < 0.001) and functional impairment (P < 0.001) were both significantly worse in patients with hyperglycemia and no prior history of DM, when compared to patients with hyperglycemia and previously diagnosed DM. Among the patients without a prior history of DM, patients with hyperglycemia were 3.4 times more likely to die within 90 days (P < 0.001) when compared with patients with normoglycemia. In contrast, the hazard ratio was 1.6 among the patients with DM (P = 0.66). CONCLUSION:Hyperglycemia on presentation is associated with significantly poorer outcomes following AIS. Patients with hyperglycemia and no prior history of DM have a particularly poor prognosis, worse than that for patients with known diabetes and hyperglycemia.
Authors: Tom Skyhoj Olsen; Peter Langhorne; Hans Christoph Diener; Michael Hennerici; Jose Ferro; Johani Sivenius; Nils Gunnar Wahlgren; Philip Bath Journal: Cerebrovasc Dis Date: 2003 Impact factor: 2.762
Authors: S E Kasner; J A Chalela; J M Luciano; B L Cucchiara; E C Raps; M L McGarvey; M B Conroy; A R Localio Journal: Stroke Date: 1999-08 Impact factor: 7.914
Authors: Maha Coucha; Weiguo Li; Sherif Hafez; Mohammed Abdelsaid; Maribeth H Johnson; Susan C Fagan; Adviye Ergul Journal: Am J Physiol Heart Circ Physiol Date: 2014-12-31 Impact factor: 4.733
Authors: Emmanuel I González-Moreno; Carlos R Cámara-Lemarroy; José G González-González; Fernando Góngora-Rivera Journal: Transl Stroke Res Date: 2014-08-03 Impact factor: 6.829
Authors: Matthew B Bevers; Neil H Vaishnav; Ly Pham; Thomas Wk Battey; W Taylor Kimberly Journal: J Cereb Blood Flow Metab Date: 2016-01-01 Impact factor: 6.200